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Background: The present study was undertaken to evaluate the anti-depressive activity of turmerone after
one-week administration by using a mouse forced swimming test (FST) and tail suspension test (TST).
Methods: Animals were divided into four groups (n = 10 /group): control (0.9% saline), the three doses of turmerone
(1.25, 2.5, 5.0 mg/kg) for one-week treatment. To assess the effect of turmerone on locomotor activity, mice were
evaluated in the open-field paradigm. Forced swimming test (FST) and Tail suspension test (TST) were used to
take as a measure of antidepressant activity. The probable mechanisms of action of the anti-depressive effect of
turmerone was also investigated by measuring the activity of monoamine oxidase-A and corticosterone levels in
the blood and the levels of monoamines in the cortex, striatum, hippocampus and hypothalamus of the mice.
Results: Turmerone (2.5, 5.0 mg/kg, p.o.) significantly reduced the immobility time of mice in both the FST and TST, but it
did not significantly affect the ambulatory and total movements of mice. However, hyperactivity might explain the results. In
addition, turmerone decreased the corticosterone level in the bloodwhile it increased the levels of 5-HT in cortex, striatum,
hippocampus, and hypothalamus, the level of NE in striatum and hippocampus, the levels of MHPG and DOPAC in
hypothalamus, the level of 5-HIAA in striatum, and the level of DA in striatum, hippocampus, and hypothalamus. Turmerone
(2.5, 5.0 mg/kg) decreased the activity of MAO-A in the frontal cortex and hippocampus of mouse brain.
Conclusions: After one-week administration, turmerone produced antidepressant-like effects. The mechanisms of
action of anti-depressive effect of turmerone seemed to involve an increase of the monoamines level decreasing
the MAO-A activity and the stress of mice.
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Depression, a highly debilitating and widely distributed
illness in the general population, is ranked by the World
Health Organization as among the most burdensome
diseases of society [1]. Affective disorder presents with
depressed mood, loss of interest or pleasure, feelings of
guilt or low self-worth, disturbed sleep or appetite, low
energy, and poor concentration [2]. An important theory
to explain the cause of depression is the monoamine
hypothesis which suggests that there is impairment of
monoaminergic functions and the decrease of serotonin,* Correspondence: df6689@yahoo.com.tw; whpeng@mail.cmu.edu.tw
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reproduction in any medium, provided the ornorepinephrine and dopamine levels [3,4]. At present, there
are several types of antidepressants used in clinical practice,
including tricyclic antidepressants (TCAs), selective sero-
tonin reuptake inhibitors (SSRIs), selective reversible in-
hibitors of monoamine oxidase A (RIMAs), and specific
serotonin–norepinephrine reuptake inhibitors (SNRIs) [5],
however, these drugs can produce many side-effects, there-
fore, considerable efforts are being invested in the discovery
of better drugs for the treatment of depression [6].
Herbal medicines such as St. John’s wort have been
used as alternative therapies for depression [7]. Curcuma
longa (Family: Zingiberaceae), also called Yu-jin in Chinese,
has long been used in food and medicine. Curcuma
drugs (e.g., C. longa) which were indicated for liver
qi stagnation in Traditional Chinese Medicine, were
selected for testing as a possible depression treatment
[8]. Turmerone, an active constituent of C. longa, has been. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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anti-tumor, and anti-proliferative activities [9-13].
Inflammation is typically characterized by redness,
swelling, pain, and heat. Depression is frequent in
chronic pain patients and it has been suggested that
pain and depression share common neurochemical
mechanisms [14]. In several studies some antidepressant
drugs afforded an integral alleviation of pain [15].
Curcumin has been shown to possess antidepressant-
like effects in animal models commonly employed for
the prediction of antidepressant activity [16-18]. It is
worthy to investigate whether turmerone, an analog of
curcumin [19], would possess antidepressant activity.
In the present study, we aimed to test the anti-depressant
effect of turmerone in mice using FST and TST.
Behavioral despair tests have good predictive value for
antidepressant potency in humans [20]. Moreover, we
determined whether the alteration of monoamine levels
and monoamine oxidase A (MAO-A) activities might
predict the antidepressant properties of turmerone. We
evaluated the effect of turmerone on the neuroendocrine
system by measuring alterations in serum corticosterone
which is involved in the mouse FST model of depression.
Methods
Animals
Male ICR mice (weighing around 22 g), purchased from
BioLASCO Taiwan Co., Ltd. (Yi-Lan, Taiwan) were used
in the present study. They were maintained at 22 ± 1°C
with free access to water and food, under a 12:12 h
light/dark cycle (lights on at 08:00 h). All manipulations
were carried out between 9:00 and 15:00 h, with each
animal used only once. All procedures in this study were
performed in accordance with the NIH Guide for the
Care and Use of Laboratory Animals. The experimental
protocol was approved by the Committee on Animal
Research, China Medical University. The minimum
number of animals and duration of observations required
to obtain consistent data were used.
Chemicals and reagents
Turmerone (CAS no. 82508-15-4) was purchased from
Allichem LLC (Baltimore, MD, USA). All drugs were
administered by oral route. The p.o. administrations
were given in a volume of 10 ml/kg body weight. Tests
were performed 1 hr after administration of turmerone.
The monoamine standards: norepinephrine (NE), dopamine
(DA), 5-hydroxytryptamine (5-HT), 4-hydroxy-3-methox-
yphenylglycol (MHPG), 3, 4-dihydroxyphenylacetic acid
(DOPAC) and 5-hydroxyindole-3-acetic acid (5-HIAA)
were purchased from Sigma-Aldrich (Steinheim, Germany).
Ethylenediamine tetraacetic acid (EDTA) was purchased
from Merck (Darmstadt, Germany). Sodium dihydrogen
phosphate monohydrate (NaH2PO4 · H2O) was purchasedfrom J.T. Baker (Phillipsburg, PA, USA). Sodium 1-octane
sulfonate was purchased from TCI (Tokyo, Japan).
Methanol and ethanol were purchased from Uni-Onward
Company (Taipei, Taiwan). All other chemicals were of
reagent grade or better.Behavior despair study
For FST and TST, animals were divided into five groups
(n = 10 /group): control (0.9% saline), FLU 10 mg/kg, and
the three doses of turmerone (1.25, 2.5, 5.0 mg/kg) for
one-week treatment.Forced swimming test (FST)
The method was carried out on mice according to the
method of Porsolt et al. [21]. Mice were placed in an
open cylindrical container (diameter 10 cm, height 25 cm),
containing 15 cm of water at 25 ± 1°C. The duration of
observed immobility was recorded during the last 4 min
of the 6-min testing period [22]. Immobile time was
defined as the absence of active/escape directed move-
ments (mouse floating in the water without struggling)
and was scored in a blind manner by an observer [23].
Decrease in the duration of immobility during the FST
was taken as a measure of antidepressant activity.Tail suspension test (TST)
The total duration of immobility induced by tail suspen-
sion was measured according to the method of Steru et al.
[24]. Mice both acoustically and visually isolated were
suspended 50 cm above the floor by adhesive tape placed
approximately 1 cm from the tip of the tail. The time
during which mice remained immobile was quantified
during a test period of 6 min. Mice were considered
immobile only when they hung passively and completely
motionless.Open-field test
For open-field test, animals were divided into four groups
(n = 10 /group): control (0.9% saline), the three doses of
turmerone (1.25, 2.5, 5.0 mg/kg) for one-week treatment.
To assess the effect of turmerone on locomotor activ-
ity, mice were evaluated in the open-field paradigm
(TRU SCAN Activity Monitoring Systems, Coulbourn
Instruments) previously described [25]. Animals were
individually placed in a box (40 × 60 × 50 cm). The mice
were not habituated to the box before the test. The mice
were placed in the center and their behavior was noted
immediately and continued for 4 min. The parameters
such as total movements, total distance, total ambulatory
move time were recorded by video camera and registered
in the computer. During the interval of the test the
apparatus was cleaned.
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levels in the mice frontal cortex, striatum, hippocampus,
and hypothalamus.
Animals were divided into five groups (n = 10/group):
control (0.9% saline), control vs. FST, FLU (10 mg/kg),
and the two doses of turmerone (2.5, 5.0 mg/kg) for
one-week treatment. The mice were killed after the FST
which was performed 1 hr after the last administration.
Monoamines were measured according to the method
of Renard et al. [26]. Briefly, mice were killed by cervical









































Figure 1 The effect of turmerone (1.25-5.0 mg/kg, p.o.), or fluoxetine
swimming (A) and tail suspension (B) tests after one week of adminis
***p < 0.001 as compared with control group (One-way ANOVA followed bbrain was removed after a rapid dissection of frontal
cortex, striatum (included the nucleus accumbens),
hippocampus and hypothalamus were isolated. The
four brain tissues were weighed, and placed separately
in 5 ml of ice-cold homogenizing solution (8.8 mg of
ascorbic acid and 122 mg of EDTA in 1000 ml of
perchloric acid 0.1 M). After homogenization, the
solution was centrifuged at 10,000 × g for 10 min at
4°C. Twenty microliters of the resultant supernatant
was injected in the high performance liquid chroma-
















(FLU, 10 mg/kg, p.o.) on the immobility time in the forced
tration. The values are mean ± SEM for each group (n = 10).

































































Figure 2 The effects of one week of turmerone administration on: (A) total movements, (B) total distance, and (C) total ambulatory
move time in the locomotion tests. The values are mean ± SEM for each group (n = 10).
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DOPAC, 5-HIAA) were measured by HPLC (Waters 610)
with electrochemical detection in the four brain tissues.
The mobile phase [4.2 g/l citric acid monohydrate,
6.8 g/l sodium acetate trihydrate, 0.8 g/l octanesulfonicTable 1 Effect of turmerone on the concentrations (ng/g tissu
mice brain
Group NE MHPG DA
Normal 402.4 ± 19.8 243.1 ± 6.2 83.5 ± 5
Control + FST 200.5 ± 23.5### 228.9 ± 15.6 48.1 ± 2
Fluoxetine 10 mg/kg + FST 283.4 ± 3.3 180.4 ± 7.6 58.7 ± 1
Turmerone 2.5 mg/kg + FST 254.9 ± 9.1 172.4 ± 5.2 69.7 ± 6
Turmerone 5.0 mg/kg + FST 384.2 ± 31.3*** 179.3 ± 5.5* 48.6 ± 8
Values were the means ± SEM (n = 10). # p < 0.05, # # p < 0.01, # # # p < 0.001 as comp
control + FST group. (One-way ANOVA followed by Scheffe’s test). NE: norepinephrin
3,4-dihydroxyphenylacetic acid, 5-HT: serotonin, 5-HIAA: 5-hydroxyindoleacetic acid.acid sodium salt, 0.05 g/l tetrasodium ethylenediamine
tetraacetate, 0.02%( v/v) dibutyl amine, and 7%( v/v)
methyl alcohol] was delivered at 1.0 ml/min. The
reverse-phase column used was a Merk Lichrospher
100 RP-18 endcapped column with a length of 12.5 cme) of monoamines and their metabolites in the cortex of
DOPAC 5-HT 5-HIAA 5-HIAA/5-HT
.6 72.2 ± 2.7 432.1 ± 22.3 127.2 ± 7.7 0.30 ± 0.03
.0## 44.6 ± 1.5 326.9 ± 15.5# 255.2 ± 41.8## 0.75 ± 0.14##
.7 47.4 ± 1.8 600.2 ± 6.1*** 214.3 ± 3.3 0.36 ± 0.01**
.3 46.9 ± 1.4 734.8 ± 18.6*** 237.0 ± 22.0 0.33 ± 0.03**
.6 42.5 ± 2.5 629.9 ± 25.5*** 250.2 ± 14.0 0.42 ± 0.02
ared with the normal group. ** p < 0.01, ***p < 0.001 as compared with the
e, MHPG: 3 methoxy-4-hydroxyphenylglycol, DA: dopamine, DOPAC:
Table 2 Effect of turmerone on the concentrations (ng/g tissue) of monoamines and their metabolites in the striatum
of mice brain
Group NE MHPG DA DOPAC 5-HT 5-HIAA 5-HIAA/5-HT
Normal 356.0 ± 9.6 238.0 ± 12.4 526.0 ± 9.2 157.7 ± 14.8 353.3 ± 18.7 214.1 ± 8.5 0.62 ± 0.05
Control + FST 262.3 ± 19.4 261.3 ± 9.6 342.9 ± 8.2### 150.1 ± 7.2 253.9 ± 9.8# 283.0 ± 2.9 1.07 ± 0.08###
Fluoxetine 10 mg/kg + FST 310.4 ± 4.7 236.2 ± 4.8 413.8 ± 5.0 144.6 ± 2.2 599.6 ± 8.8*** 204.7 ± 3.4 0.34 ± 0.01***
Turmerone 2.5 mg/kg + FST 379.1 ± 43.2* 256.4 ± 3.3 933.5 ± 23.1*** 129.7 ± 5.6 852.8 ± 15.3*** 206.4 ± 5.6* 0.26 ± 0.01***
Turmerone 5.0 mg/kg + FST 327.8 ± 12.7 253.3 ± 6.8 776.9 ± 23.8*** 137.5 ± 5.3 731.8 ± 17.6*** 204.2 ± 20.9* 0.28 ± 0.03***
Values were the means ± SEM (n = 10). # p < 0.05, ### p < 0.001 as compared with the normal group. * p < 0.05, ** p < 0.01,***p <0.001 as compared with the control
+ FST group. (One-way ANOVA following by Scheffe’s test). NE: norepinephrine, MHPG: 3 methoxy-4-hydroxyphenylglycol, DA: dopamine, DOPAC: 3,4-dihydroxy-
phenylacetic acid, 5-HT: serotonin, 5-HIAA: 5-hydroxyindoleacetic acid.
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The compounds were measured at +0.75 V using a
Bioanalytical Systems LC-4C electrochemical detector.
Measurements of monoamine oxidase (MAO) activity
Animals were divided into four groups (n = 10/group):
control (0.9% saline), and two doses of turmerone (2.5,
5.0 mg/kg, for one week’ administration). The mice were
killed after the FST which was performed 1 hr after the
last administration.
Mouse brain fraction was prepared following the
procedure described previously [27]. Briefly, the fraction
suspended in 10 volume of cold sodium phosphate
buffer (10 mM, pH 7.4, containing 320 mM sucrose), was
mingled at 48°C for 20 min. The mixture was centrifuged
at 15,000 g for 30 min at 8°C and the pellets were
re-suspended in the same buffer. The protein concen-
tration was adjusted to 1 mg/ml. Protein concentration
was measured by the Lowry method [28] using bovine
serum albumin as the standard. The MAO activity was
assessed spectrophotometrically as described previously
[8]. The assay mixtures contained 4 mM 5-HT as specific
substrates for MAO-A, 250 ml solution of the fraction,
and 100 mM sodium phosphate buffer (pH 7.4) up to a
final volume of 1 ml. The reaction was allowed to proceed
at 37°C for 20 min, and stopped by adding 1 M HCl
(200 ml), the reaction product was extracted with 5 ml of
butyl acetate (for MAO-A assay). The organic phase was
measured at wavelength of 280 nm for MAO-A assay
with spectrophotometer, respectively. Blank samples wereTable 3 Effect of turmerone on the concentrations (ng/g tissu
hippocampus of mice brain
Group NE MHPG DA
Normal 290.6 ± 23.8 244.4 ± 14.9 50.1 ± 2
Control + FST 220.3 ± 10.3 257.0 ± 11.8 41.9 ± 1
Fluoxetine 10 mg/kg + FST 299.7 ± 5.2 243.0 ± 5.3 49.6 ± 1
Turmerone 2.5 mg/kg + FST 398.0 ± 31.8*** 228.0 ± 15.2 82.7 ± 2
Turmerone 5.0 mg/kg + FST 386.1 ± 11.9*** 227.0 ± 18.8 60.4 ± 1
Values were the means ± SEM (n = 10). ### p < 0.001 as compared with the normal g
followed by Scheffe’s test). NE: norepinephrine, MHPG: 3 methoxy-4-hydroxyphenyl
5-HIAA: 5-hydroxyindoleacetic acid.prepared by adding 1 M HCl (200 ml) prior to reaction,
and worked up subsequently in the same manner.
Blood sampling and corticosterone measurement
Animals were divided into four groups (n = 6 /group):
control (0.9% saline), control vs. FST, the two doses of
turmerone (2.5, 5.0 mg/kg) for one-week treatment.
The animals were sacrificed 1 hr after the last adminis-
tration for blood sampling between 04:00 and 06:00 p.m.
The abdominal aorta was punctured under intramuscu-
lar (i.m.) ketamine hydrochloride (10%, 0.35 ml) and
medetomidine hydrochloride (0.001%, 0.05 ml) anesthesia.
The collected blood was heparinized and centrifuged
by 400 g for 10 min. Corticosterone was measured with
an automatic chemiluminescence Immunoassay system
(Advia Centaur, Bayer, Bad Nauheim, Germany) [29].
Statistical analysis
All results are expressed as mean ± SEM. Data were ana-
lyzed by one-way ANOVA followed by Scheffe’s multiple
range test. The criterion for statistical significance was
p<0.05. All statistical analyses were carried out by using
SPSS for Windows (SPSS Inc.).
Results
Turmerone caused a reduction in the immobility time in
FST (F (4, 45) = 346.4) and TST (F (4, 45) = 249.8) (dose
range: 1.25–5.0 mg/kg, p.o.; Figure 1).
Turmerone did not affect total movement and ambu-
latory movement at the same doses that significantlye) of monoamines and their metabolites in the
DOPAC 5-HT 5-HIAA 5-HIAA/5-HT
.0 31.9 ± 0.7 406.5 ± 14.7 198.9 ± 3.5 0.51 ± 0.03
.4 38.0 ± 1.1 216.6 ± 5.5### 216.1 ± 9.6 1.01 ± 0.07###
.4 31.0 ± 1.8 400.0 ± 5.2*** 194.0 ± 6.2 0.49 ± 0.02***
.0*** 31.5 ± 0.9 489.1 ± 12.1*** 176.8 ± 13.7 0.37 ± 0.03***
.8*** 31.5 ± 0.8 573.1 ± 20.5*** 185.5 ± 24.9 0.32 ± 0.05***
roup. ***p <0.001 as compared with the control + FST group. (One-way ANOVA
glycol, DA: dopamine, DOPAC: 3,4-dihydroxyphenylacetic acid, 5-HT: serotonin,
Table 4 Effect of turmerone on the concentrations (ng/g tissue) of monoamines and their metabolites in the
hypothalamus of mice brain
Group NE MHPG DA DOPAC 5-HT 5-HIAA 5-HIAA/5-HT
Normal 267.4 ± 7.7 201.6 ± 7.8 437.3 ± 13.0 111.0 ± 7.9 345.6 ± 21.8 145.7 ± 13.5 0.44 ± 0.06
Control + FST 207.5 ± 3.2 217.9 ± 8.8 343.6 ± 12.9### 183.4 ± 7.9 216.7 ± 10.4### 238.0 ± 13.8## 0.11 ± 0.05###
Fluoxetine 10 mg/kg + FST 224.7 ± 2.6 202.5 ± 3.1 363.1 ± 3.3 143.1 ± 3.2 422.7 ± 3.3*** 204.6 ± 3.4 0.48 ± 0.10***
Turmerone 2.5 mg/kg + FST 246.1 ± 11.0 166.9 ± 16.4* 555.3 ± 11.4*** 124.2 ± 7.7* 483.0 ± 18.5*** 219.7 ± 14.0 0.45 ± 0.02***
Turmerone 5.0 mg/kg + FST 230.6 ± 13.0 196.2 ± 3.0 436.6 ± 11.6*** 157.3 ± 16.1 539.4 ± 10.5*** 225.4 ± 13.8 0.42 ± 0.02***
Values were the means ± SEM (n = 10). ## p < 0.01, ### p < 0.001 as compared with the normal group. * p < 0.05, ***p < 0.001 as compared with the control + FST
group. (One-way ANOVA followed by Scheffe’s test). NE: norepinephrine, MHPG: 3 methoxy-4-hydroxyphenylglycol, DA: dopamine, DOPAC: 3,4-dihydroxyphenyla-
cetic acid, 5-HT: serotonin, 5-HIAA: 5-hydroxyindoleacetic acid.
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(Figure 2). The total distance [F (3, 36) = 10.5] increase
caused by 2.5 mg/kg turmerone may result from an
increased movement speed.
As shown in Tables 1, 2, 3, and 4, turmerone (2.5 mg/
kg, p.o.) increased the level of 5-HT in cortex, striatum,
hippocampus, and hypothalamus, the level of NE in
striatum and hippocampus, the level of MHPG and
DOPAC in hypothalamus, the level of 5-HIAA in striatum,
and the level of DA in striatum, hippocampus, and hypo-
thalamus. Turmerone (5.0 mg/kg, p.o.) increased the level
of 5-HT in striatum, hippocampus and hypothalamus,
the level of 5-HT in cortex, the level of 5-HIAA in
striatum, the level of NE in cortex and hippocampus,
and the level of DA in striatum, hippocampus, and
hypothalamus. Furthermore, turmerone (2.5, 5.0 mg/
kg, p.o.) decreased serotonin turnover ratio (5-HIAA/5-
HT) in cortex, striatum, hippocampus, and hypothalamus.
Table 5 summarizes the effect of turmerone on the
activities of MAO-A in mouse brain. Turmerone (2.5,
5.0 mg/kg) decreased the activity of MAO-A in the
frontal cortex and hippocampus of mouse brain.
As shown in Figure 3, after the one-week treatment,
turmerone (2.5-5.0 mg/kg) significantly decreased the
levels of serum corticosterone in mice according to the
swim stress test.
Discussion
Traditional Chinese Medicine is widely held to beneficial
but generally neither the active principles nor their
molecular targets are well defined [19], therefore, an




Control 11.4 ± 1.1 22.6 ±
Turmerone 2.5 mg/kg 8.1 ±0.8** 22.2 ±
Turmerone 5.0 mg/kg 7.0 ± 0.3** 22.4 ±
Values were the means ± SEM (n = 10). * p < 0.05, **p < 0.01 as compared with themechanism(s) of action can make such medicines more
acceptable.
The FST and TST are behavioral despair tests useful
for probing the pathological mechanism of depression
and for the evaluation of antidepressant drugs [30].
These tests are also a well-established system for screening
new potent antidepressant drugs in mice [21]. Charac-
teristic behavior scored in both tests is termed immo-
bility, reflecting a behavioral state of despair (learned
helplessness), as seen in human depression [24]. In
order to investigate whether turmerone can produce
chronic changes in depression-related behavior in FST
and TST, we treated mice for one-week with different
dosages via daily oral administration. Turmerone caused
a reduction in the immobility time in FST and TST
(Figure 1). The results presented here show, to our
knowledge for the first time, that turmerone given orally is
effective in producing significant antidepressant-like
activity, when assessed in the FST and TST.
In FST and TST, anti-depressants can also be distin-
guished from stimulants, because stimulants cause marked
motor stimulation, in contrast to antidepressants, which
do not [31]. In order to determine whether turmerone
actually possesses an antidepressant-like activity, we
tested the locomotion counts to exclude the excitatory
or inhibitory effects after administration of turmerone.
Turmerone did not affect total movement and ambulatory
movement at the same doses that significantly reduced
immobility response in the FST and TST (Figure 2). The
total distance increase caused by 2.5 mg/kg turmerone
may result from an increased movement speed, so this
should be further studied in the future. This hyperactivity5.0 mg/kg, p.o.) on MAO-A activity in different regions of
Activity of MAO-A (U·h-1·mg-1)
um Hippocampus Hypothalamus
3.0 29.6 ± 1.0 40.0 ± 1.9
0.6 24.8 ± 1.2 36.6 ± 1.7
0.6 22.7 ± 0.9* 37.2 ± 4.3
































Control         FST             2.5              5.0
Turmerone (mg/kg, p.o.)
Figure 3 The effects of turmerone (2.5-5.0 mg/kg) for one
week’ administration on serum corticosterone levels in the
mouse FST. Data are expressed as mean ± SEM (n = 6/group). For
statistical significance, # p < 0.05 compared to vehicle-treated control
group, ***p < 0.001 compared to vehicle-treated FST group.
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immobility time in FST and TST.
Most currently clinically employed antidepressants exert
their effects predominantly on one monoaminergic system,
although it is unlikely that pharmacological manipulation
of a single neurotransmitter in relative isolation would
produce changes sufficient to remedy severe neuro-
chemical dysfunction [32]. There is abundant evidence
from anatomical, electrophysiological and pharmacological
studies that the interactions between neurotransmitter
systems are important [31]. Four brain regions were
studied: the frontal cortex, the striatum, the hippocampus,
and the hypothalamus, which are involved in important
behavioral functions, such as emotion, motivation and
learning and memory [33,34]. Abnormal monoamine
levels in the four brain regions may be relevant to the
depressed state. As shown in Tables 1, 2, 3, and 4, tur-
merone (2.5 mg/kg, p.o.) increased the level of 5-HT in
cortex, striatum, hippocampus, and hypothalamus, the
level of NE in striatum and hippocampus, the level of
MHPG and DOPAC in hypothalamus, the level of 5-HIAA
in striatum, and the level of DA in striatum, hippocampus,
and hypothalamus. Turmerone (5.0 mg/kg, p.o.) increased
the level of 5-HT in striatum, hippocampus and hypothal-
amus, the level of 5-HT in cortex, the level of 5-HIAA
in striatum, the level of NE in cortex and hippocampus,
and the level of DA in striatum, hippocampus, and
hypothalamus. These results indicated that the effect of
turmerone on depression may be mediated via the
increase in monoamines levels in the hippocampus,
cortex, striatum, and hypothalamus of mice. Furthermore,
turmerone (2.5, 5.0 mg/kg, p.o.) decreased serotonin
turnover ratio (5-HIAA/5-HT) in cortex, striatum, hippo-
campus, and hypothalamus. This result indicated thatturmerone increased the level of serotonin in cortex,
striatum, hippocampus, and hypothalamus. MAO is an
important enzyme in the metabolism of a wide range
of monoamine neurotransmitters, including NE, DA,
and 5-HT.
MAO-A inhibitors are efficacious for treating depression
while the inhibitors of MAO-B appear to be effective in
preventing and treating Parkinson’s disease. Furthermore,
a positive correlation between oxidative stress and depres-
sion [35] is reported in some studies. Turmerone (2.5,
5.0 mg/kg) decreased the activity of MAO-A in the frontal
cortex and hippocampus of mouse brain. The HPA axis
plays a key role in the physiological response to various
stressful situations [36]. Continuous activation of the HPA
axis, especially abnormally increased serum corticosterone
levels, leads to hormonal imbalance and even to more
severe diseases such as depressive disorder both in
rodents and humans [37,38]. The FST is known to be a
potent activator of the HPA axis [39]. After the one-
week treatment, turmerone (2.5-5.0 mg/kg) significantly
decreased the levels of serum corticosterone in mice
according to the swim stress test (Figure 3). The result
strongly suggested that turmerone exerted antidepressant
activity, at least in part, by regulating serum corticosterone
levels, thus normalizing the HPA axis hyperactivity.
Conclusion
In conclusion, turmerone reduced immobility time in
the mouse FST and TST. The results suggest that the
antidepressant-like effect of turmerone in FST is mediated,
at least in part, by the inhibition of MAO-A, and reversed
the swim stress -induced increases in serum cortico-
sterone levels. Our study suggest that turmerone possess
potent antidepressant properties.
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